Pre-intervention trend | Post-intervention | |||||
---|---|---|---|---|---|---|
Immediate impact of the formulary change | Change in trend after the formulary change | |||||
Coefficient | 95% confidence interval | Coefficient | 95% confidence interval | Coefficient | 95% confidence interval | |
DDD/100 stays-day | ||||||
Total ICS-LABA | − 0.464 | − 2.117 to 1.188 | 3.344 | − 10.312 to 17.002 | 0.317 | − 1.359 to 1993 |
Formoterol/budesonidea | 0.012 | − 1.438 to 1.464 | 15.830* | 3835 to 27,825 | − 0.200 | − 1.672 to 1,272 |
Salmeterol/fluticasoneb | − 1.043 | − 2.483 to 0.396 | − 7.792* | − 15.113 to − 0.471 | 1.075 | − 0.37 to 2.521 |
Inpatient expenditure per DDD | ||||||
Total ICS-LABA | − 0.003 | − 0.119 to − 0.113 | − 0.953* | − 1.733 to − 0.174 | 0.009 | − 0.108 to 0.127 |
DDD/TID | ||||||
Total ICS-LABA | − 0.405 | − 1.046 to 0.235 | 0.994 | − 1.484 to 3.474 | 0.348 | − 0.290 to 0.986 |
Formoterol/budesonide | 0.066 | − 0.102 to 0.235 | − 0.015 | − 0.820 to 0.790 | − 0.068 | − 0.238 to 0.101 |
Salmeterol/fluticasone | − 0.039 | − 0.194 to 0.115 | − 0.143 | − 0.991 to 0.704 | 0.034 | − 0.121 to 0.190 |
Formoterol/beclometasone | − 0.008 | − 0.141 to 0.123 | − 0.182 | − 0.817 to 0.453 | − 0.030 | − 0.164 to 0.102 |
Formoterol/fluticasone | 0.006 | − 0.021 to 0.033 | 0.107 | − 0.103 to 0.319 | 0.001 | − 0.026 to 0.029 |
Vilanterol/fluticasone | 0.008 | − 0.01 to 0.027 | − 0.023 | − 0.154 to 0.107 | − 0.017 | − 0.037 to 0.002 |
Outpatient expenditure per DDD | ||||||
Total ICS-LABA | − 0.405 | − 1.046 to 0.235 | 0.994 | − 1.484 to 3.474 | 0.348 | − 0.290 to 0.986 |